Updated Jun 17, 8:17 PM · 60 sources analyzed
Key Takeaways
Jazz Pharmaceuticals commits up to $4B with AbCellera to build a T cell engager pipeline targeting solid tumors beyond current blood cancer indications.
Eli Lilly terminated its Phase 2 LY3541860 rheumatoid arthritis program while completing a Phase 3 combo psoriasis-obesity trial; results pending for both.
Three bioRxiv preprints advance mRNA delivery science and dual-target liver/infection biology, with no peer review yet completed.
🏆 Winner
Jazz Pharmaceuticals — secured a high-value multispecific antibody platform deal positioning it as a credible next-generation immuno-oncology developer
📉 Loser
Eli Lilly — LY3541860 rheumatoid arthritis program terminated, reducing near-term immunology pipeline depth
🔭 Watch Next
Results from Eli Lilly's completed Phase 3 ixekizumab plus tirzepatide psoriasis-obesity study have not yet been disclosed and represent a near-term data catalyst for both the dermatology and metabolic disease markets.
Jazz Pharmaceuticals bets $4B on next-gen T cell engagers
Jazz Pharmaceuticals signed a collaboration with AbCellera worth up to $4 billion to develop next-generation T cell engagers (antibodies that redirect the immune system to kill cancer cells) and multispecific antibodies. The deal reflects industry-wide effort to extend T cell engager technology beyond blood cancers, where current approvals are concentrated, into solid tumors. For competitors, this signals rising deal valuations for multispecific antibody platforms and continued consolidation of early-stage immunotherapy assets by mid-size pharma.
BioPharma Dive ↗Boehringer Ingelheim
Spesolimab in Hidradenitis suppurativa (HS) — long-term treatment
Specific figures not disclosed. Study status listed as TERMINATED on ClinicalTrials.gov; no results posted in source.
Why it matters
Termination of the long-term spesolimab HS program removes a potential IL-36 receptor inhibitor entrant from a crowded HS market now anchored by AbbVie's secukinumab and adalimumab.
Eli Lilly and Company
LY3541860 in Moderately to severely active rheumatoid arthritis
Specific figures not disclosed. Study status listed as TERMINATED on ClinicalTrials.gov; no efficacy results posted in source.
Why it matters
Termination of LY3541860 in rheumatoid arthritis narrows Lilly's pipeline in immunology beyond its approved assets, though the company retains a broad portfolio in this space.
Jazz Pharmaceuticals / AbCellera
Jazz Pharmaceuticals and AbCellera entered a collaboration worth up to $4 billion to discover and develop T cell engagers and multispecific antibodies across oncology indications.
The deal extends competitive pressure on established immuno-oncology players by adding Jazz as a funded developer of next-generation T cell redirecting therapies, a modality so far dominated by Amgen, Genentech, and J&J in hematology.
BioPharma Dive ↗Eli Lilly and Company
Ixekizumab + Tirzepatide in Moderate-to-severe plaque psoriasis with obesity or overweight
Specific figures not disclosed. Study status listed as COMPLETED on ClinicalTrials.gov; no results posted in source.
Why it matters
Combining an IL-17A inhibitor (ixekizumab) with a GIP/GLP-1 receptor agonist (tirzepatide) could establish a new standard for patients with both inflammatory skin disease and obesity, expanding tirzepatide's commercial footprint beyond metabolic indications.
Specific figures not disclosed. Study status listed as COMPLETED on ClinicalTrials.gov; no results posted in source.
Why it matters
Combining an IL-17A inhibitor (ixekizumab) with a GIP/GLP-1 receptor agonist (tirzepatide) could establish a new standard for patients with both inflammatory skin disease and obesity, expanding tirzepatide's commercial footprint beyond metabolic indications.
Specific figures not disclosed. Study status listed as TERMINATED on ClinicalTrials.gov; no efficacy results posted in source.
Why it matters
Termination of LY3541860 in rheumatoid arthritis narrows Lilly's pipeline in immunology beyond its approved assets, though the company retains a broad portfolio in this space.
Specific figures not disclosed. Study status listed as COMPLETED on ClinicalTrials.gov; no results posted in source.
Why it matters
BMS-986012 (an anti-fucosyl-GM1 antibody) added to the nivolumab plus chemotherapy backbone is a key test of whether additional tumor-targeting antibodies can improve outcomes in a disease where progress has been incremental.
Specific figures not disclosed. Study status listed as COMPLETED on ClinicalTrials.gov; no results posted in source.
Why it matters
Completion of this safety and immunogenicity study advances Pfizer's mRNA platform into respiratory indications beyond COVID-19, where it competes directly with Moderna and other mRNA developers.
Specific figures not disclosed. Study status listed as TERMINATED on ClinicalTrials.gov; no results posted in source.
Why it matters
Termination of the long-term spesolimab HS program removes a potential IL-36 receptor inhibitor entrant from a crowded HS market now anchored by AbbVie's secukinumab and adalimumab.
Jazz Pharmaceuticals / AbCellera
Jazz Pharmaceuticals and AbCellera entered a collaboration worth up to $4 billion to discover and develop T cell engagers and multispecific antibodies across oncology indications.
Why it matters
The deal extends competitive pressure on established immuno-oncology players by adding Jazz as a funded developer of next-generation T cell redirecting therapies, a modality so far dominated by Amgen, Genentech, and J&J in hematology.
Bile salt analogs show dual activity against fatty liver disease and C. difficile infection
Novel bile salt analogs (modified versions of naturally occurring digestive compounds) reduced lipid accumulation in liver cells in preclinical models while also showing activity against Clostridioides difficile, a common gut infection, according to a bioRxiv preprint.
Why it matters
A single compound class addressing both MASLD (metabolic dysfunction-associated steatotic liver disease, a form of fatty liver) and C. difficile could open a new therapeutic niche, particularly relevant given the clinical overlap between the two conditions.
Stereochemistry of lipid nanoparticles affects protein expression via internal lipid organization
A bioRxiv preprint reports that the three-dimensional shape (stereochemistry) of lipids used in nanoparticle delivery vehicles modulates how much protein is produced from mRNA cargo, through changes in internal lipid structure.
Why it matters
For mRNA drug and vaccine developers, stereochemical selection of ionizable lipids could become a tunable lever to optimize delivery efficiency and reduce required doses, with implications for cost and tolerability.
iRhom2 adapter protein critically drives acute lung inflammation via ADAM17 activation
A bioRxiv preprint demonstrates that iRhom2, an adapter protein expressed mainly in immune cells, is required for ADAM17-mediated shedding of pro-inflammatory molecules including TNF and IL-6 receptor during acute lung injury.
Why it matters
Selective targeting of iRhom2 rather than the broader ADAM17 enzyme could offer a more precise anti-inflammatory strategy with a potentially better safety profile for conditions like ARDS and sepsis.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Regeneron filed an 8-K with the SEC disclosing Item 5.07 (results of a shareholder vote). Specific voting details were not included in the source summary.
SEC EDGAR ↗Two Lilly-sponsored trials updated status on ClinicalTrials.gov: a Phase 3 study of ixekizumab plus tirzepatide in psoriasis with obesity (COMPLETED) and a Phase 2 study of LY3541860 in rheumatoid arthritis (TERMINATED). No efficacy figures were disclosed in either source.
ClinicalTrials.gov ↗A Phase 2 study of BMS-986012 (anti-fucosyl-GM1 antibody) combined with carboplatin, etoposide, and nivolumab in extensive-stage small cell lung cancer was listed as COMPLETED on ClinicalTrials.gov; no results were disclosed in the source.
ClinicalTrials.gov ↗A Phase 1/2 study of Pfizer's modified RNA influenza vaccine in healthy adults was listed as COMPLETED on ClinicalTrials.gov, and a Phase 3 study of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer remains ACTIVE_NOT_RECRUITING. No results were disclosed in either source.
ClinicalTrials.gov ↗